Young-Jun Shin

This inventor holds 17 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Modulators. Top assignees: Arena Pharmaceuticals, Inc., Arisan Therapeutics Inc.. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Young-Jun Shin. Retrieved from https://idiyas.com/inventor/young-jun-shin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 64.7

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 7.1

ph-index = 6

Forward Citations = 154(Granted Patents)

Location History:

San Digeo, CA (US) (2009)
San Diego, CA (US) (2006 - 2024)

Company Filing History:

16 out of 218

Arena Pharmaceuticals, Inc.

patents

1 out of 4

Arisan Therapeutics Inc.

patents

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

Prostacyclin Receptor

Beta-3 Adrenergic Receptor

Heterocyclic Compounds

Pyrazolyl Derivatives

Aryl Derivatives

Metabolism Modulators

Carbonic Acid Derivatives

Fused-Aryl Derivatives

Trisubstituted Derivatives

Heart Failure Treatment

Arenavirus Treatment

Metabolic Disorders

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50267 - Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto (2025-01-14),

2. 11987588 - Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto (2024-05-21),

3. 11352328 - Heterocyclic compounds for the treatment of arenavirus (2022-06-07),

4. 11339172 - Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto (2022-05-24),

5. 11098034 - Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto (2021-08-24),

6. 10689372 - Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto (2020-06-23),

7. 10668033 - Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto (2020-06-02),

8. 10214518 - Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto (2019-02-26),

9. 9663500 - Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto (2017-05-30),

10. 9012478 - Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto (2015-04-21),

11. 8895776 - Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto (2014-11-25),

12. 8546429 - 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto (2013-10-01),

13. 8410119 - Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto (2013-04-02),

14. 7838525 - Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto (2010-11-23),

15. 7625906 - Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto (2009-12-01),

Title: **Young-Jun Shin: A Pioneer in Pharmacological Innovations**

Introduction

Young-Jun Shin, based in San Diego, CA, is a distinguished inventor recognized for his substantial contributions to the pharmaceutical field. With a remarkable portfolio of 17 patents, he has dedicated his career to advancing the treatment of various medical conditions through innovative drug formulations and therapies.

Latest Patents

Among his latest patents are significant advancements in the modulation of the prostacyclin (PGI2) receptor and the beta-3 adrenergic receptor. His invention concerning modulators of the prostacyclin receptor focuses on novel amide derivatives that offer potential treatments for pulmonary arterial hypertension (PAH) and numerous related disorders, such as coronary artery disease, stroke, and chronic obstructive pulmonary disorder (COPD). Additionally, his work on beta-3 adrenergic receptor modulators provides new avenues for addressing heart failure and associated conditions. These patents exemplify his innovative approach to tackling complex biomedical challenges.

Career Highlights

Throughout his career, Young-Jun Shin has worked with reputable companies, including Arena Pharmaceuticals, Inc. and Arisan Therapeutics Inc. His endeavors at these organizations have facilitated the development of groundbreaking treatments that aim to improve patient outcomes in various therapeutic areas. Shin's expertise in pharmacology and drug design has positioned him as a key figure in the field.

Collaborations

Young-Jun Shin has collaborated with notable colleagues, such as Thuy-Anh Tran and Ning Zou. Together, they have contributed to advancing research and innovation, highlighting the importance of collaboration in the field of pharmaceutical development.

Conclusion

In summary, Young-Jun Shin has made significant contributions to medical science through his innovative inventions and extensive patent portfolio. His commitment to addressing critical health issues through pharmaceutical innovation showcases the vital role of inventors in developing effective treatments. As the landscape of healthcare continues to evolve, Shin's work will undoubtedly inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.